HLB BioStep Co

HLB BioStep Co Net Debt per Share

The Net Debt per Share of HLB BioStep Co (278650.KQ) as of Nov 18, 2026 is 20.93 KRW. In the previous year, Net Debt per Share was -462.68 KRW — a change of -104.52% (higher).

Net Debt per Share

20.93KRW

YoY

-104.52%

Last updated:

Net Debt per Share of HLB BioStep Co is 2025 20.93 KRW. Net Debt per Share of HLB BioStep Co was 2024 -462.68 KRW. It decreases by -104.52% higher compared to the previous year.

The HLB BioStep Co Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
45.66 KRW
Jan 1, 2019
-113.50 KRW
Jan 1, 2020
-129.42 KRW
Jan 1, 2021
24.13 KRW
Jan 1, 2022
-105.26 KRW
Jan 1, 2023
-771.44 KRW
Jan 1, 2024
-462.68 KRW
Jan 1, 2025
20.93 KRW
The HLB BioStep Co Net Debt per Share history
YEARNet Debt per ShareYoY
20.93KRW-104.52%
-462.68KRW-40.02%
-771.44KRW+632.91%
-105.26KRW-536.26%
24.13KRW-118.64%
-129.42KRW+14.03%
-113.50KRW-348.59%
45.66KRW-144.71%
-102.11KRW+252.11%
-29.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HLB BioStep Co Stock analysis

What does HLB BioStep Co do? HLB bioStep Co., Ltd. generates revenue through three business segments. The Non-clinical Test Consignment Agency Business segment provides testing for new drugs and evaluates efficacy, pharmacodynamics, and safety of substances. The Bioinfra Business segment designs, constructs, and maintains animal laboratories while delivering equipment. The Pet Medical Business segment develops veterinary medicine and sells companion animal products. Clients include pharmaceutical companies requiring non-clinical testing, research institutions needing laboratory infrastructure, and pet care providers purchasing animal health products. The company's Non-clinical Test Consignment Agency Business serves pharmaceutical firms seeking pre-market substance evaluation. Bioinfra Business targets institutions requiring specialized animal lab facilities and equipment. Pet Medical Business supplies veterinary medicine to pet health markets. Revenue streams are derived from testing fees, laboratory services, equipment sales, and product distribution. HLB bioStep's segments align with pharmaceutical development cycles, animal research infrastructure needs, and companion animal healthcare demands. Testing services are contracted by drug developers, lab construction by research organizations, and veterinary products sold to pet care retailers. The company monetizes expertise in non-clinical testing, lab management, and veterinary product distribution without direct consumer sales. HLB BioStep Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HLB BioStep Co stock

Net Debt per Share of HLB BioStep Co is 20.93 KRW in 2025.

Net Debt per Share of HLB BioStep Co changed from -462.68 KRW to 20.93 KRW, representing a -104.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share HLB BioStep Co since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — HLB BioStep Co

All Key Metrics — HLB BioStep Co